{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Yojana Gadiya",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "PUBCHEM": "^\\d+$",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns"
    },
    "namespaces_uncached": [],
    "path": "huntington/loi2018.bel",
    "pybel_version": "0.13.3-dev"
  },
  "links": [
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Huntington’s disease (HD) is an autosomal dominant progressive neurogenerative disorder that is characterised by cognitive, behavioural and motor dysfunction (see associated Paper 1 on neuropsychiatric manifestations and diagnosis of HD).",
      "key": "b4ed03f401bd3eed421affd8c11a225665cf9d8fd720da6842cf95709dd67ecbdc8460b3981cbb2efeb6e001825b2e92487bf107253b32d2c205a265366c5d1c",
      "line": 80,
      "relation": "association",
      "source": 18,
      "target": 23
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Huntington’s disease (HD) is an autosomal dominant progressive neurogenerative disorder that is characterised by cognitive, behavioural and motor dysfunction (see associated Paper 1 on neuropsychiatric manifestations and diagnosis of HD).",
      "key": "57a3b24469403e04ae1d97979069946ba436f3c8c176058de275b5eb96dc4903f2ca8b0580dddec74a9eec8fb520b5066a7943424d61d340be17ee85d552e4c8",
      "line": 81,
      "relation": "association",
      "source": 18,
      "target": 29
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Huntington’s disease (HD) is an autosomal dominant progressive neurogenerative disorder that is characterised by cognitive, behavioural and motor dysfunction (see associated Paper 1 on neuropsychiatric manifestations and diagnosis of HD).",
      "key": "2e965717415d039853d976f13da7ca383bdca4b16b0f7c1e84443fac651593eda2f1d5b4cfbbdb1ebf01e31ac53d34eeed9fb15befd8157e02f2a47c2140bdb8",
      "line": 82,
      "relation": "decreases",
      "source": 18,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Huntington’s disease (HD) is an autosomal dominant progressive neurogenerative disorder that is characterised by cognitive, behavioural and motor dysfunction (see associated Paper 1 on neuropsychiatric manifestations and diagnosis of HD).",
      "key": "9930cce79c040fd0403f21c5f7e3d3f73198b989aa0861cbe28de93c938da892a50cf7a7b2c04de7bca86baf9d096f3eb7003a96fc9e8f49afe11fed24f764fc",
      "line": 83,
      "relation": "decreases",
      "source": 18,
      "target": 13
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "bc467909bbf8f6019975ccb36ceffec52e2e91fadb7fab51143c5ec3498b0a7b8cd8d7947d9a5df95e8b6092a1e64c2d01b9b83ac30221972373317819758eb8",
      "line": 88,
      "relation": "association",
      "source": 18,
      "target": 28
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "b68b71f649308d83abbae5920c2196357d0027aaf668a01f7945532e5acc398efac7fac92586a8f9e4a78c4e28f73b92da62dab55befacdd1d688aa9c6fe75c4",
      "line": 89,
      "relation": "association",
      "source": 18,
      "target": 31
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "3b8d94c876b52032de3a4bed72cab82a32a77c79d577f4058f68cc1d45cb8292516e22e6248baf38f2e41777a7ec32941dfdad23b633851f33cfc05656b802b5",
      "line": 94,
      "relation": "association",
      "source": 18,
      "target": 21
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "37951f5726ea9c95f6d6f2e901b3eaab47d0a4c39feb3ee1ec4d3bb87421841fa296609639d1ff04a6891c1453d6ec6cbcba8cacf9205059ce72aa8d5eb26278",
      "line": 96,
      "relation": "association",
      "source": 18,
      "target": 3
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Mood disorders: depressive symptoms may predate the onset of motor symptoms by many years and can occur throughout the course of the disease.",
      "key": "acde90a79216b993115b480b60e2c7cb77a25ccfeeb62516def967235d6a68b12f9dbf04c6835f5035d1e2507694b96bb0dd2818f7b3e472793e51f30d76346d",
      "line": 122,
      "relation": "association",
      "source": 18,
      "target": 30
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Mood disorders: depressive symptoms may predate the onset of motor symptoms by many years and can occur throughout the course of the disease.",
      "key": "ef155be323576cedd94994733438c921c3641e588b55db601ca7d296372ae3eef9384209d75a2bd0ac591f60eff523c169989608b390239fa3ad0bc5b2f3d72d",
      "line": 123,
      "relation": "association",
      "source": 18,
      "target": 20
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Some people who are gene positive for HD may have a primary psychotic disorder such as schizophrenia that predates their movement disorder for many years.",
      "key": "21531f490ae93a9ad23b12340134b027a911057bd686bcb94865cb5dd10f442e343be7b0e5f2ecef5d187f3c74ca36009ebf2da2acd213a21b41b280066b0539",
      "line": 129,
      "relation": "association",
      "source": 18,
      "target": 25
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "The cognitive impairment seen in HD is a form of subcortical dementia characterised by slowing of thought processing, executive dysfunction and memory impairment.",
      "key": "0d811b815c91203ebd53377cc5a702acc3127d5425017a7bb4e0b35f5eeaf71bea3c27a56f45337665f40d16529961b3a54611cbbda9cdbaabf8432de12ed61d",
      "line": 164,
      "relation": "association",
      "source": 18,
      "target": 16
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There have been a large number of therapeutic trials with the aim of improving motor and cognitive symptoms of HD, targeting the major neurotransmitters implicated in HD such as amantadine or pridopidine (glutamate and dopamine antagonists, respectively).",
      "key": "507288cb9fa8d8930cfd1792221f65040baee6adf2a916466f803aa20dea638f30482da7d0df5b2b5c7a83d3107ee661f1bd791f3229bf3c81953641e84b4c92",
      "line": 185,
      "relation": "association",
      "source": 18,
      "target": 0
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There have been a large number of therapeutic trials with the aim of improving motor and cognitive symptoms of HD, targeting the major neurotransmitters implicated in HD such as amantadine or pridopidine (glutamate and dopamine antagonists, respectively).",
      "key": "ed09eb4e6f3dd4b1f0578234d9325298a5eedf0502101adaa3afd4ac1815314614ce6a4aa7aeb8dfa66e7c6a1949fa9bff4d502b2bd18c4a350cd0f4df795cd2",
      "line": 187,
      "relation": "association",
      "source": 18,
      "target": 12
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Huntington’s disease (HD) is an autosomal dominant progressive neurogenerative disorder that is characterised by cognitive, behavioural and motor dysfunction (see associated Paper 1 on neuropsychiatric manifestations and diagnosis of HD).",
      "key": "021f3b461a18dd7775049f7c2a16dad1bdd9cdf30785e8f4617ea801046d2ca2ed437ff477ed11204273eab862afddb265348bd120bdd85d3f3d09c6e0551670",
      "line": 80,
      "relation": "association",
      "source": 23,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Huntington’s disease (HD) is an autosomal dominant progressive neurogenerative disorder that is characterised by cognitive, behavioural and motor dysfunction (see associated Paper 1 on neuropsychiatric manifestations and diagnosis of HD).",
      "key": "ef06208b9bb7ba4cddc37a1b49498e28b5f6ffa8e2785f2771a3734dd2ab981ca88c5dc6fd3d9c7224a2fd212af093f29adaf3d56b0c30d0621cd42f5aa30825",
      "line": 81,
      "relation": "association",
      "source": 29,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "f6bb831f2152f0152d05cc25cfec6269a940c3a52316ea69b00d5e87f98ed06de160adc64cf73a0e9b998cb90b366fd8f11cc9b1236604c985c8ad004cca6a57",
      "line": 88,
      "relation": "association",
      "source": 28,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "c4ebde73d76268e0f101c464fb6ff24f97c58a180b1167e45911dc7b3b596f1d1b6fc1f4be9647f4b399a8ad54154390698099109648b334e2cff5c92be44199",
      "line": 90,
      "relation": "association",
      "source": 28,
      "target": 21
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "9371dee38c94794a2b59325c010531513c52171380dea91a84538904b5e7709c626b5872681e1737f5998a7b61041c9b94464693a32d8e9a5a8cf9f4f7a0be0a",
      "line": 92,
      "relation": "association",
      "source": 28,
      "target": 3
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "ac46cfbe774fab768428cd784e5615d2bf0ccf2c61c9af47ddd5868131b881303ab12ee9998d41d91c991c46c2178a9857ba89caaae5de647401c4e4c1ef4902",
      "line": 89,
      "relation": "association",
      "source": 31,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "b9dccbb49f75fa46c1b79a759187dc4989f8a846181edd1b4090977f06dff2ccaf88e18c4b38e897fe067983c527da10b264c8fb0e752e2fd933087e6764b0be",
      "line": 91,
      "relation": "association",
      "source": 31,
      "target": 21
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "f2895a0b6c6ca5856b938c7af327901dfdbf7acdcae62a5d069fa552010d1c8a8eb7303a9728b6fd32a57b1657f3eb210c0f3b60865ae5e5f3e4be2b036bdd1a",
      "line": 93,
      "relation": "association",
      "source": 31,
      "target": 3
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "407a9066737bc4e996ed3a6257ca1a7db36eef221fbfec35febd30f71c0ce3df42ba1ef8c66b9447b99853fc7c2972681b0cee49ce96410a3ab17dd61c494e4e",
      "line": 90,
      "relation": "association",
      "source": 21,
      "target": 28
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "84dbe18e200366c89c05691e3da4ab8e9680f3d51720f4698c0c56dc167c3ff277de709d73bf07e2c3fd9d9f0a839dd841a6c7872b71e1fafe24723ab6fd4145",
      "line": 91,
      "relation": "association",
      "source": 21,
      "target": 31
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "be4a860ab899e919d732b3e9ba317987e445738b6971e2f96612847fe0ecd303630a028ac80c78271a40e89b7e288a065c7d330020432ef230a378219f5358ad",
      "line": 94,
      "relation": "association",
      "source": 21,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "be5118673e1f3e93b7e2e30d5303039af69ceaf81eb52d956bb9a5281d070c05fe05ad532d472c6c7f3c644c61140151dd6e4795eda14970fb6a7f9c77293904",
      "line": 92,
      "relation": "association",
      "source": 3,
      "target": 28
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "d35184923ca157a9b3f4dd55b1561987a709cb3cbc8cc10ab6b1d04963d0d23441fd1b44b3c330b63a46eed9483e17df25abc95fab0984e7030718c4914d1330",
      "line": 93,
      "relation": "association",
      "source": 3,
      "target": 31
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Abnormal movements (chorea, dystonia) in HD are due to changes in neural circuitry and neurotransmitters such as dopamine.",
      "key": "d1a3795c3ff8360da3495cded3c1237fda4e2449d5d275e3934d70223506d7303f7785a3055e0ec1677c60a3fd44f3c736087dd5515c75b1dc4c6c687392f897",
      "line": 96,
      "relation": "association",
      "source": 3,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "In the initial stages, dopamine antagonists such as risperidone and olanzapine can be used to suppress the abnormal movements.",
      "key": "6212735c334294e2827929b29742f73a27895e95e4d30a4fe07da6c3db663749f100a6e3412b21584724663ee94e8de12fe427ad08412270f6a46d7db0f670ba",
      "line": 103,
      "relation": "decreases",
      "source": 5,
      "target": 3
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "In the initial stages, dopamine antagonists such as risperidone and olanzapine can be used to suppress the abnormal movements.",
      "key": "82702198338aaa65d08c48f580bda7908a733b9e4c86f86e3248a19d4f24dc1d218102df7d275bb6e4ec9ef1eda6d00805f263c4160a9c25cebde24c78d14ab3",
      "line": 105,
      "relation": "decreases",
      "source": 5,
      "target": 28
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "In the initial stages, dopamine antagonists such as risperidone and olanzapine can be used to suppress the abnormal movements.",
      "key": "3486ddfd67e58a8e89a54d0fcc379446498fb3f4bdff90c5049f06db072326d4424d9df4e6f7c0264afa991be1c6baec4d24c4242b0f3d52e987e5da50e59714",
      "line": 107,
      "relation": "decreases",
      "source": 5,
      "target": 31
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Risperidone may be considered firstline as it can also suppress the movement disorder.",
      "key": "51c140604ef46177747252d776da915b2e6d78b3ae13bf9e410153e115e676b72966c23d66500ccbb06d75ee1b6effc38a751d29a0f4a1040a5fb31ca81b239b",
      "line": 134,
      "relation": "decreases",
      "source": 5,
      "target": 26
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "In the initial stages, dopamine antagonists such as risperidone and olanzapine can be used to suppress the abnormal movements.",
      "key": "9d115cc08800ed061f03179f7efd37d767ca4bb275aa1edc3af826bb80bf3a8e32b3265bb2f7795b928312ae1e4079302bbf304c5cf723b506e457699c284fa1",
      "line": 104,
      "relation": "decreases",
      "source": 4,
      "target": 3
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "In the initial stages, dopamine antagonists such as risperidone and olanzapine can be used to suppress the abnormal movements.",
      "key": "ab507c1c2b8558e96de08121b0f736414a090fd1a2b7dde42805a5a95a0504fe0191ed04ea7654923baadcd3dc1a99549221c9df7f64c93814efb2dae4e0e36e",
      "line": 106,
      "relation": "decreases",
      "source": 4,
      "target": 28
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "In the initial stages, dopamine antagonists such as risperidone and olanzapine can be used to suppress the abnormal movements.",
      "key": "6d6dfedbdc0c256650e04d0fc34e1b15eda43d09dfb0e0d4317ff91c0bd2cfcf5fee729b047e2f9160ca32f60295d6ee55d497ac9190d8ab37744e98e222e61e",
      "line": 108,
      "relation": "decreases",
      "source": 4,
      "target": 31
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "In April 2017, the FDA approved the use of deutetrabenazine, a long-acting form of tetrabenazine, which was successfully found to reduce chorea in a randomised controlled trial (RCT) of 90 patients (FIRST-HD).",
      "key": "b31362099404eff38e9a14b0dd8c41a7ffb8b2ee1041c99cbcf1edf0d14a93ee02bc56309e6d33f6cda642f32030be7e70eb7a6e45be10595dfd3b53b8360dcb",
      "line": 115,
      "relation": "isA",
      "source": 11,
      "target": 10
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "In April 2017, the FDA approved the use of deutetrabenazine, a long-acting form of tetrabenazine, which was successfully found to reduce chorea in a randomised controlled trial (RCT) of 90 patients (FIRST-HD).",
      "key": "71156a36ba9010c51aa173365baf732e480a42172e7120ec639b0ce39cb0e692f2f5dfc937bcc04d1494c136d2bcd61fce8b6583a343866e889a37f26c376935",
      "line": 116,
      "relation": "decreases",
      "source": 11,
      "target": 28
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Mood disorders: depressive symptoms may predate the onset of motor symptoms by many years and can occur throughout the course of the disease.",
      "key": "9a393c623f2534b67f70ad81d0755b9e76aa1e8768127c5b3f46e1e1e4c0bfbe6c0c4d1bb869715b07d953b816c41be3fa33fa9e8a01e68adb30ef98ea48f079",
      "line": 122,
      "relation": "association",
      "source": 30,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Mood disorders: depressive symptoms may predate the onset of motor symptoms by many years and can occur throughout the course of the disease.",
      "key": "88c66bd5480665455303dfe831a4eb8adeb6fabdf68362147af20066f6c9af3c347baced490a0b0e8d87885c2515453fb46210d91ac5d373055082334d9930bd",
      "line": 123,
      "relation": "association",
      "source": 20,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Some people who are gene positive for HD may have a primary psychotic disorder such as schizophrenia that predates their movement disorder for many years.",
      "key": "77a12f094b4fdbef95c201be56f3ec3531fa944df2d0c8ecf3d2d83de8d2760140a4ce79a82bf6b12c69f997f92df3884bd233ff1b7be9095820891a1a005fef",
      "line": 129,
      "relation": "association",
      "source": 25,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Some people who are gene positive for HD may have a primary psychotic disorder such as schizophrenia that predates their movement disorder for many years.",
      "key": "1c01d0992b6df270189f4ef30eaa823ce0c5f62b051fecb81bc55ede6edeec5c61e6e7eca24b90dec60dd1321ed895f605aa4fa913d19690cda5661112b59c14",
      "line": 130,
      "relation": "decreases",
      "source": 25,
      "target": 33
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There are few large studies using psychotropic medications in HD-related irritability and aggression.Mood stabilisers such as valproate and carbamazepine and selective serotonin reuptake inhibitors (SSRIs) can be used.",
      "key": "1a5f478cee69089546197abc8220f2086467d9796fdf33ff5ea1ffdb1a2f3e30b9f0ff49c875dd6517b20ad2a49d2fc5962251ace303dfa4c77cb113e2711f83",
      "line": 143,
      "relation": "decreases",
      "source": 7,
      "target": 19
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There are few large studies using psychotropic medications in HD-related irritability and aggression.Mood stabilisers such as valproate and carbamazepine and selective serotonin reuptake inhibitors (SSRIs) can be used.",
      "key": "60b71f27684e0a7152361834134359a85aee8131b0c3600dc23e08f8d959a98851b413b47ec157eec04eecce22bf45dfbd845fe8bfb71fc0d55b1465ad2bb71a",
      "line": 146,
      "relation": "decreases",
      "source": 7,
      "target": 27
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There are few large studies using psychotropic medications in HD-related irritability and aggression.Mood stabilisers such as valproate and carbamazepine and selective serotonin reuptake inhibitors (SSRIs) can be used.",
      "key": "34d50d57f6b60483b75f7d3c8f5b7d46599433a6e5883efe89c3d29729e9037f0023aab8cea080d5a7df1f2ed48e4ab094e7d6a257df2382653135978b4bed20",
      "line": 144,
      "relation": "decreases",
      "source": 1,
      "target": 19
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There are few large studies using psychotropic medications in HD-related irritability and aggression.Mood stabilisers such as valproate and carbamazepine and selective serotonin reuptake inhibitors (SSRIs) can be used.",
      "key": "a27981b6c6eb6ba49b82fdca6ae95791789a6184cc4838130fdb87f46dfe1304ee9bbe6b8439aa4dd075168cedf214dd7f18b325451a5eaef39d8d2c314337a7",
      "line": 147,
      "relation": "decreases",
      "source": 1,
      "target": 27
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There are few large studies using psychotropic medications in HD-related irritability and aggression.Mood stabilisers such as valproate and carbamazepine and selective serotonin reuptake inhibitors (SSRIs) can be used.",
      "key": "3751af30be1ea9ecf092e576afa2a51b7b7b14b464d9c4a55002c3f74f42137d964a6bd86423b7eaeb53118efc03f32f52b6f8cae9b2342407a900cd201ad0fa",
      "line": 145,
      "relation": "decreases",
      "source": 8,
      "target": 19
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There are few large studies using psychotropic medications in HD-related irritability and aggression.Mood stabilisers such as valproate and carbamazepine and selective serotonin reuptake inhibitors (SSRIs) can be used.",
      "key": "069d531d53d81c382bb8a822d7ee0948006fec760c7923b03f765a7c585de5ffbcb5f0e47dc51a35ace0fb7aacc556efca14ea690186034d0de0cd96ffa5b242",
      "line": 148,
      "relation": "decreases",
      "source": 8,
      "target": 27
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Obsessive-compulsive symptoms, repetitive behaviours, inflexibility and rigidity can also be thought of as part of the frontal dysexecutive syndrome, and SSRIs and clomipramine can be used if these are present, though behavioural strategies are also recommended.",
      "key": "24de6ee66e52dc0e23de558278bf9098c0e1b65a95043fe74d14c68fcc93aad7fcfa472f9a1bd7026f447ad8a3729e9acbc5df96bf92ae154aac59f07b30cdf2",
      "line": 157,
      "relation": "decreases",
      "source": 8,
      "target": 24
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Obsessive-compulsive symptoms, repetitive behaviours, inflexibility and rigidity can also be thought of as part of the frontal dysexecutive syndrome, and SSRIs and clomipramine can be used if these are present, though behavioural strategies are also recommended.",
      "key": "d3f3c7c559436de02dc0c330422d382caf177268162c9bff220136366e6664197ef30f1f8a4f51dc66de040f2ff3dc34ae305dc182f446d79c0b03499af21b1f",
      "line": 158,
      "relation": "decreases",
      "source": 2,
      "target": 24
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "The cognitive impairment seen in HD is a form of subcortical dementia characterised by slowing of thought processing, executive dysfunction and memory impairment.",
      "key": "22b2578bda3487078f8b542b8f217caf27837b679769a48559ca1aef1d6d4c538619f7cb58a77e8f146f5a03a77098d3c1fbedd2de62226bf324e537d184396c",
      "line": 164,
      "relation": "association",
      "source": 16,
      "target": 18
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "The cognitive impairment seen in HD is a form of subcortical dementia characterised by slowing of thought processing, executive dysfunction and memory impairment.",
      "key": "70b59377350ec8ed1927c9d52ab829c65be13a1e22be2b8aeeb5db423472330d75d663242906ed37210dd8fde6ab4e2ee0bcce7458e8e1d0d90b80a5444f71d0",
      "line": 165,
      "relation": "isA",
      "source": 16,
      "target": 22
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "The cognitive impairment seen in HD is a form of subcortical dementia characterised by slowing of thought processing, executive dysfunction and memory impairment.",
      "key": "0dadbde0f0c0f05ae01b9543b486b8f2616b39e43cbbd7d8e6108b6d7550abd1d6dc80d4f90eaa932aac5e080336c481dce82e8b150377fa3af9fd980322f26d",
      "line": 166,
      "relation": "decreases",
      "source": 16,
      "target": 34
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "The cognitive impairment seen in HD is a form of subcortical dementia characterised by slowing of thought processing, executive dysfunction and memory impairment.",
      "key": "8ae87ce0e7d1f472005c895ee80b93f57a0ffe391067529288c272f6ce6cae3de3887103c05819a5b250977d054ce8c752f2f6b2b178ebb3696edb0c07dd1400",
      "line": 167,
      "relation": "decreases",
      "source": 16,
      "target": 17
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "The cognitive impairment seen in HD is a form of subcortical dementia characterised by slowing of thought processing, executive dysfunction and memory impairment.",
      "key": "6f5b314819df5a06a2463555f9a6bd33010e60691086903ece05345c207a5d40d51d2b1ff4a1a07ea3b960092e9f054e34374a2a8ada8aa76d3e536eb03067fb",
      "line": 168,
      "relation": "decreases",
      "source": 16,
      "target": 32
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "A study of rivastigmine in 11 patients with HD suggested improvement in motor scores and a trend towards improvement in cognition and functional scores, but more study is required.[6]",
      "key": "32f61c80e87a465688e2b49672667903f26c9f911a8d42aa754cea86570aca50e57691669a2377937bf60334ea5436377388f4240f60a6cc049dc3853dbfa665",
      "line": 175,
      "relation": "increases",
      "source": 6,
      "target": 13
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "A study of rivastigmine in 11 patients with HD suggested improvement in motor scores and a trend towards improvement in cognition and functional scores, but more study is required.[6]",
      "key": "5ec2b2ca89c8c1a988c9151acf23ca4b58369b54a6c87226bab5958589ecaafaaf06933ddfd58e56653a8e5dee1e071ab52f560c804ebe928212094aa9a3bb74",
      "line": 176,
      "relation": "increases",
      "source": 6,
      "target": 29
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There have been a large number of therapeutic trials with the aim of improving motor and cognitive symptoms of HD, targeting the major neurotransmitters implicated in HD such as amantadine or pridopidine (glutamate and dopamine antagonists, respectively).",
      "key": "9ce06762e4d87892466897b65551212c2ed713e731a0fc355268304631b9ca10bad77d0b34790600683a0f9c91dbd03430da9caeb8f99cb70024820c28ba4220",
      "line": 184,
      "relation": "decreases",
      "source": 0,
      "target": 9
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There have been a large number of therapeutic trials with the aim of improving motor and cognitive symptoms of HD, targeting the major neurotransmitters implicated in HD such as amantadine or pridopidine (glutamate and dopamine antagonists, respectively).",
      "key": "15c1ea6de831ccbe2c6f90812d0da6c9aa244e36e6391cf1ec6e01047a2babd1135ddde40d35fb958223889f364b5f4eff42500b65d17152441a8100a6537d53",
      "line": 185,
      "relation": "association",
      "source": 0,
      "target": 18
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Targeting the glutamate system, amantadine, an NMDAreceptor antagonist, has had limited success in improving some of the features of HD.",
      "key": "4e819f79d2ec645c86bdeb13080881b37ceaf8bf978567c1543795ca33d6e1fa0653d2b395bf45720b9be53a9e9cf4a9ccc6a6992fec4e333d241c5f6eacb068",
      "line": 202,
      "relation": "decreases",
      "source": 0,
      "target": 15
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There have been a large number of therapeutic trials with the aim of improving motor and cognitive symptoms of HD, targeting the major neurotransmitters implicated in HD such as amantadine or pridopidine (glutamate and dopamine antagonists, respectively).",
      "key": "08adb0c822dd76a49e50d1bff4150e1c6cbb660543c366268c20d62463e37553fcda57f1876d321733e8fad5b61fa0147d60b6eddfbdd65327372ca9d7e8b905",
      "line": 186,
      "relation": "decreases",
      "source": 12,
      "target": 3
    },
    {
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "There have been a large number of therapeutic trials with the aim of improving motor and cognitive symptoms of HD, targeting the major neurotransmitters implicated in HD such as amantadine or pridopidine (glutamate and dopamine antagonists, respectively).",
      "key": "0399d6dc217a57b458a45982194722d976e80fe1dae953f574b825e243ba0cc0d85ed79826c3085fc78133d86091c9073949397724b3d26f7edc59caa41aa9cf",
      "line": 187,
      "relation": "association",
      "source": 12,
      "target": 18
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Huntington Disease": true
        }
      },
      "citation": {
        "authors": [
          "Loi SM",
          "Looi JC",
          "Velakoulis D",
          "Walterfang M"
        ],
        "date": "2018-08-01",
        "first": "Loi SM",
        "last": "Looi JC",
        "name": "Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists",
        "pages": "376-380",
        "reference": "29687724",
        "title": "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.",
        "type": "PubMed",
        "volume": "26"
      },
      "evidence": "Results from 2016 showed that pridopidine did not improve the motor symptoms of HD; however, there was a statistically significant improvement in the Total Functional Capacity score, which could be interpreted as delay in functional decline.[7]",
      "key": "d67d74097a89ac625028a06716d567885153fea07880b083380a3faa9e416616a4600ab8630b4edf7043b1453b74ab3af75d8704b970a98426a11366be7a6481",
      "line": 195,
      "relation": "causesNoChange",
      "source": 12,
      "target": 13
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:amantadine)",
      "function": "Abundance",
      "id": "620f716f419b74a42ca68a554b5c1bef6fcca88972b4a3afdb4151b9076a3b9fa2bbc153af1c0a32ed9fc094d3639183987389dd5adffde04bbdb674fe545131",
      "name": "amantadine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:carbamazepine)",
      "function": "Abundance",
      "id": "0384749fb8f5fbc026e05adc85f09466afbc894f62164f3a3c20ab892a7437ea6107ce26f8e08f5e1e00231ed753cc40c89145faa101157f2891a4258ce5b988",
      "name": "carbamazepine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:clomipramine)",
      "function": "Abundance",
      "id": "c587d64287abbbd252b06051278d4276791726aff07b107f5bed46281a973a7f9e5a6141ea299472edfaed606c0eabf6d33d4e4dc78546d6937734bff00fbb75",
      "name": "clomipramine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:dopamine)",
      "function": "Abundance",
      "id": "70f7314679db5bae3c2260b6feff9a6ef3407fb6a585f92a58c59fd066a2ec279c0091a72edba3465c4f2aa033afff7fded0b16c4a84f4bbcecd092a934ea66e",
      "name": "dopamine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:olanzapine)",
      "function": "Abundance",
      "id": "1bf66087499cac14a4ab63d9d758c6751c642681b14f4777719f1213f96696771d5b77e870709d17c178eee352d72f62ec32400b447d3d226585f2922224d63c",
      "name": "olanzapine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:risperidone)",
      "function": "Abundance",
      "id": "45c347ad3652ed13e12fab0139a1dbcf2884f0fd79e62c9cb6a034adad36e702c2d1acc54e429b192e848190a7a379b8a2c0e488a7be5a57408d1ba7fd0927af",
      "name": "risperidone",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:rivastigmine)",
      "function": "Abundance",
      "id": "317d5b18448e148088204c7a7dce78316c0ea8b56c70a7adaffe344826b17688e05873b2746050d29c18ae658658e81a2d775ba56b6f5abf8821f4eaca725064",
      "name": "rivastigmine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:valproate)",
      "function": "Abundance",
      "id": "9820cb8440fcbbaad2586f1b24e84080ebf3fac392f1e7084b69316e8ab094d15603faa1bd2d571d8fe7647e300e36a5d825edad35c88288f49a6664c64ef707",
      "name": "valproate",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(MESH:\"Serotonin Uptake Inhibitors\")",
      "function": "Abundance",
      "id": "605d8c29b6f98ab526f74c78bf5639910a302c0a9f5156d0a842b33b294d0b3300230a3c99414a6d540c0f9ba319f4216f048b80569925c7ac9db9b6b8a7f90f",
      "name": "Serotonin Uptake Inhibitors",
      "namespace": "MESH"
    },
    {
      "bel": "a(PUBCHEM:33032)",
      "function": "Abundance",
      "id": "4a470a9ceb0e588fe72ddce7a25958d21864ca91fe6df312aa52b9b97bb8fe0386e26498233bfe84d4074b29f9bb5ea08e3da6a0fc888ca325ecbfe98a5607d3",
      "name": "33032",
      "namespace": "PUBCHEM"
    },
    {
      "bel": "a(PUBCHEM:6018)",
      "function": "Abundance",
      "id": "965c0d7822cf5a597a74264967c88505f34e7f6e2d93838817fff57bfa94e826d4104c05fbc807d323e82b85845d033706826f184a8eb605ae79438a861092e0",
      "name": "6018",
      "namespace": "PUBCHEM"
    },
    {
      "bel": "a(PUBCHEM:73437646)",
      "function": "Abundance",
      "id": "582af7b6a933711d42c14dbaab54e68d14c5d03cfc019a893909fe88f7fb01afba7b0f6c21811373d29ee24cd17a932f84a5de75e29740872cab1b598c48f418",
      "name": "73437646",
      "namespace": "PUBCHEM"
    },
    {
      "bel": "a(PUBCHEM:9795739)",
      "function": "Abundance",
      "id": "e12e8bf0611fb3f7f6c45426c4054f192c6e9e965785646e1f25ea712c7975d23f76957e175bad331be66f11da246966f0f35eb44da30e452ef003a8a4e7e3dd",
      "name": "9795739",
      "namespace": "PUBCHEM"
    },
    {
      "bel": "bp(GO:\"motor behavior\")",
      "function": "BiologicalProcess",
      "id": "181472b7f9a4b32696b87492619020f88bad9e24f439e97158614801e3fb1dda434c97b95c252baa65a43ba7d78eecfca26f91f6a5295d37b21e6873f04a73f6",
      "name": "motor behavior",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:behavior)",
      "function": "BiologicalProcess",
      "id": "9a101ba3d87b5d6d86780d7ab27c7ab65e2d60e8abbe894683aa3ad6755eb311c595c8a088174655a14224a317985b6ec4db3d3c829671b156af6e3f4d6cae36",
      "name": "behavior",
      "namespace": "GO"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Glutamate ionotropic receptor NMDA type subunits\")",
      "function": "Protein",
      "id": "04fcb6dc2a3a7372aafa9bcd0a67ae080105125c80681cd13f078d8204e354557b8a3cb1bfac030ca24c27787cd42c4ee35ef15010057fba33439f6190647fd7",
      "name": "Glutamate ionotropic receptor NMDA type subunits",
      "namespace": "HGNCGENEFAMILY"
    },
    {
      "bel": "path(MESH:\"Cognitive Dysfunction\")",
      "function": "Pathology",
      "id": "bd78fa3131dd9ef6067a5fe3ee8689c946c79d0da1bedb054d1f4400b9ad0d3ae041837faa0fbacee0af5a57a4cd343d11e73fd53fd05269e3558803a56df69c",
      "name": "Cognitive Dysfunction",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Executive Function\")",
      "function": "Pathology",
      "id": "49eccc7c6474d853d3f7d9f266a96b278d78b96c15d0f1691b4c116f7c58d193008d088b30c310c4af65bda65369134dc12957dfb47cb73fc2eecaeeead3efe2",
      "name": "Executive Function",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Huntington Disease\")",
      "function": "Pathology",
      "id": "1879e0f73bb6f3f680c5793e5c3b9370792a52545c46d4ee9f41a8ef46edd5ba61400e77effb39bd0d1e7f3de6470e091c5d8e6c5beed8d780456b6740a4406c",
      "name": "Huntington Disease",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Irritable Mood\")",
      "function": "Pathology",
      "id": "dc32a53f051746432afab52fac575e8aa4e99d2cdd367c7191e349adc6121926797504d078531450781cc1fbc5b6d9e6adc02060cedb821fa7e01971e764cb0b",
      "name": "Irritable Mood",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Motor Disorders\")",
      "function": "Pathology",
      "id": "de533e6c384fbd82a035846f8bacbfe0b05a1669df76ade1b87351c17ffc233fc4a2b5b33af6e10b173aa257f030e2f8527a86d5ddbc2655b306c1253498558f",
      "name": "Motor Disorders",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Neural Pathways\")",
      "function": "Pathology",
      "id": "e63c4698a558235340c07558ab0a97a666652d32f4d92ba6bc097d2dc94dab5c480fdfe0254bf415a4090b3b7a08ee571da5ffaf0e0337974a0ce4b65806b6a1",
      "name": "Neural Pathways",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Neurocognitive Disorders\")",
      "function": "Pathology",
      "id": "d3d5ea522d64cf4692e545e3196ba8cec0782cc17665d25e239f114eb2d8fb51563674a7e71fee360f1b87d5a3e240f8e2560417178af514803d6e331ec80f66",
      "name": "Neurocognitive Disorders",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Neurodegenerative Diseases\")",
      "function": "Pathology",
      "id": "95863a6d11beb3bd993523e1c8c7e210d281b0c092553f6a4cf27dd3ecf2fa51b49c5056b8aed6f7ac7c82f99101c34bc9fc0afc3dce117fe011d159ba9e4c89",
      "name": "Neurodegenerative Diseases",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Obsessive-Compulsive Disorder\")",
      "function": "Pathology",
      "id": "416439c93738dd6e4ea529e2ffebdcd0af4d47de3a98f92ae19ad224db65b554ef5530ac40174df80bc63978bd3926b0589ca8f747f12ee7b6de2e9108b5936c",
      "name": "Obsessive-Compulsive Disorder",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Schizophrenia, Disorganized\")",
      "function": "Pathology",
      "id": "de2cfd897525c77f8768631b62fe26e647d2558849058933225b8f21158a82ab7d59966a12967fdda74e239a67ff6a336fd1f4f579edab8857ed77e7223f96c5",
      "name": "Schizophrenia, Disorganized",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Stereotypic Movement Disorder\")",
      "function": "Pathology",
      "id": "34a33d12b815172cadec5aee6c083a25fd7471f53eb675e0957dde5d98223a5dce24576330fc4b720b9259341d5d61f6f31f4ea4f3e5d751a9fb96420c794223",
      "name": "Stereotypic Movement Disorder",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Aggression)",
      "function": "Pathology",
      "id": "3baeef036ebf13d97eca7c5edfc7cc5122a6600f1a2268e272b2854e3605dd8bfb4d55a0539aec790d0cecd4977770e57a9961252552e9add740de8bfe2c276e",
      "name": "Aggression",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Chorea)",
      "function": "Pathology",
      "id": "2b4d35982bd7b14a015899b0fbf69581027fc723a4b49eac9a96024415efd458c2f401874bc224607f5388e6b218e0ead9ef7e566137fde8d79910ab3df79c9f",
      "name": "Chorea",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Cognition)",
      "function": "Pathology",
      "id": "d8ff6334a72a605de87a6f1c577433b40d5732bc0387acd31217452afe3e60a4d5928028b8b819ce892d4784459379ebea852781c6e1c96bc81d3270f4a06b5a",
      "name": "Cognition",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Depression)",
      "function": "Pathology",
      "id": "1db8d744eac9b5ac408852b1889bb0b09e0054ea091932f1aa44aeeab0ea1b3825912c55c72fb2d25d5848e77d62b1c6a1df2063a2f25ae03e5ca30085922799",
      "name": "Depression",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Dystonia)",
      "function": "Pathology",
      "id": "aec7e80d4f48a5c0b4e1a6770a1a988548fffc07736ec8abff2d0bcbab97790ec012a79a9f9d0148c7c8009a0acf385010e5f95ffc770fab760ee63d7bbbc00c",
      "name": "Dystonia",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Memory)",
      "function": "Pathology",
      "id": "458f0dcf7b803807dba1023338bdb4a2f225d390c38b33a8972f9ff63b677d58adabbb4ad1bd00d2986334b90861fc40c133593b338b3873bf033d5e09af1322",
      "name": "Memory",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Movement)",
      "function": "Pathology",
      "id": "f5a025ce3c8ecad0b34f2bc22c0c2b824a22580b7fe76e17344bc0360f71136cc13b0eb1b3ce13aff810d9654f2bdf8b9ee3481ee2f36837d890002a0891fc89",
      "name": "Movement",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Thinking)",
      "function": "Pathology",
      "id": "247be1419fd72a3011b27cb437ca5b5b89844c8975199e87b4b15fe2d23f2d238f7214927c567dbbc59b28de50a96de0f4f988f102ce33ba5632d0ee15aebd76",
      "name": "Thinking",
      "namespace": "MESH"
    }
  ]
}